Jpmorgan Chase & CO Alx Oncology Holdings Inc Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 357,957 shares of ALXO stock, worth $640,743. This represents 0.0% of its overall portfolio holdings.
Number of Shares
357,957
Previous 236,046
51.65%
Holding current value
$640,743
Previous $394,000
43.91%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ALXO
# of Institutions
68Shares Held
31.6MCall Options Held
53.8KPut Options Held
11.7K-
Ven Bio Partners LLC San Francisco, CA9.7MShares$17.4 Million4.29% of portfolio
-
Redmile Group, LLC San Francisco, CA3.39MShares$6.07 Million0.17% of portfolio
-
Tang Capital Management LLC San Diego, CA3.16MShares$5.65 Million0.08% of portfolio
-
Black Rock Inc. New York, NY2.69MShares$4.81 Million0.0% of portfolio
-
Almitas Capital LLC Santa Monica, CA2.54MShares$4.54 Million0.5% of portfolio
About ALX ONCOLOGY HOLDINGS INC
- Ticker ALXO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,747,100
- Market Cap $72.9M
- Description
- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...